The restructuring of the supply agreement, particularly the reduction in the transfer price of Ameluz, is likely to improve Biofrontera Inc.'s financial margins on the product. Additionally, taking control of the US clinical trials could streamline operations and potentially accelerate the development process for Ameluz in the US market. These factors are generally positive for the company's outlook, suggesting a likely positive impact on the stock price in the short term.